Trial intelligence / Profile preview

Soraprazan in Stargardt disease

2018-001496-20Phase 2Completed

Sponsor
Katairo
Start
Nov 2018
Modality
Small Molecules
Countries
1
01

Overview

Phase 2, randomised, double-blind trial in Fundus Flavimaculatus (FF) comparing Soraprazan with Placebo (2 arms). Primary endpoint: Change in qAF8 score from baseline to Month 12. Started Nov 2018; status: completed.

02

Drugs

soraprazan
03

Conditions

Fundus Flavimaculatus (FF)

Beyond the preview

Go deeper on 2018-001496-20.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2018-001496-20.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call